Altimmune, Inc. (NASDAQ:ALT – Get Rating) has earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokerages […]
Sectoral Asset Management Inc. grew its holdings in Altimmune, Inc. (NASDAQ:ALT – Get Rating) by 27.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 342,500 shares of the company’s stock after acquiring an additional 73,400 shares during the period. Sectoral Asset Management […]
Sectoral Asset Management Inc. increased its position in shares of Altimmune, Inc. (NASDAQ:ALT – Get Rating) by 27.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 342,500 shares of the company’s stock after acquiring an additional 73,400 shares during the quarter. Sectoral Asset Management Inc.’s holdings in Altimmune were worth $5,634,000 at the […]
Landscape Capital Management L.L.C. bought a new position in shares of Altimmune, Inc. (NASDAQ:ALT – Get Rating) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 28,975 shares of the company’s stock, valued at approximately $477,000. Landscape Capital Management L.L.C. owned 0.06% of Altimmune as […]
Shares of Altimmune, Inc. (NASDAQ:ALT – Get Rating) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target […]